Brief: Standard BioTools Enters Strategic Sale Of SomaLogic To Illumina
23/06/2025 12:11
June 23 (Reuters) - STANDARD BIOTOOLS- DEAL VALUED AT UP TO $425 MILLION WITH $350 MILLION UPFRONT STANDARD BIOTOOLS ENTERS NEXT PHASE OF TRANSFORMATION WITH STRATEGIC SALE OF SOMALOGIC TO ILLUMINA Source text: ID:nGNX14Dxx Further company coverage: ILMN.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Standard BioTools
See all newsBrief: Standard Biotools Announces Agreement To Sell Microfluidics Business To Archimed
Brief: Standard Biotools Provides Update On Sale Of Mass Cytometry Business
Standard BioTools Inc. reports results for the quarter ended June 30 - Earnings Summary
Standard BioTools Q2 revenue falls on consumables weakness
Brief: Standard BioTools Q2 EPS USD -0.07